The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5.16% during 2023-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.
Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body.
They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.
Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.
Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
2. What is the expected growth rate of the global erythropoietin drugs market during 2024-2032?
3. What are the key factors driving the global erythropoietin drugs market?
4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
5. What is the breakup of the global erythropoietin drugs market based on the drug class?
6. What is the breakup of the global erythropoietin drugs market based on the product type?
7. What is the breakup of the global erythropoietin drugs market based on the application?
8. What is the breakup of the global erythropoietin drugs market based on the end-user?
9. What are the key regions in the global erythropoietin drugs market?
10. Who are the key players/companies in the global erythropoietin drugs market?
Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body.
They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.
Erythropoietin Drugs Market Trends:
At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market.Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.Drug Class Insights:
- Biologics
- Biosimilars
Product Type Insights:
- Epoetin-alfa
- Epoetin-beta
- Darbepoetin-alfa
- Others
Application Insights:
- Hematology
- Kidney Disorder
- Cancer
- Others
End-User Insights:
- Hospitals
- Homecare
- Specialty Clinics
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Questions Answered in This Report
1. How big is the global erythropoietin drugs market?2. What is the expected growth rate of the global erythropoietin drugs market during 2024-2032?
3. What are the key factors driving the global erythropoietin drugs market?
4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
5. What is the breakup of the global erythropoietin drugs market based on the drug class?
6. What is the breakup of the global erythropoietin drugs market based on the product type?
7. What is the breakup of the global erythropoietin drugs market based on the application?
8. What is the breakup of the global erythropoietin drugs market based on the end-user?
9. What are the key regions in the global erythropoietin drugs market?
10. Who are the key players/companies in the global erythropoietin drugs market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Erythropoietin Drugs Market
6 Market Breakup by Drug Class
7 Market Breakup by Product Type
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Amgen Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- F. Hoffmann-La Roche AG
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- LG Chem Ltd.
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 11 Billion |
| Forecasted Market Value ( USD | $ 17.3 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
